Genomma Lab achieves **22.1%** Top Line Growth and a **18.1%** Net Income Growth in Second Quarter of 2013

Genomma Lab Internacional Announces its Second Quarter 2013 Results

Mexico City, Mexico –July 24th, 2013

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB.B) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended June 30, 2013. All figures included herein are stated in nominal Mexican pesos and were prepared in accordance with International Financial Reporting Standards (IFRS). As of January 1st of 2012, the Company adopted IFRS as the accounting framework for its financial statements to comply with the provisions established by the Mexican National Banking and Securities Commission (CNBV).

2Q 2013 Highlights (vs. 2Q 2012)

- Net Sales for the second quarter reached Ps. 2.53 billion, increasing 22.1%, compared to the same period of 2012.
- During the second quarter, sales from our Mexican operations increased 5.9% to Ps. 1.50 billion, compared to the same quarter of 2012.
- Sales from our international operations increased 57.1% in the second quarter to Ps. 1.03 billion, compared to the same quarter of 2012.
- EBITDA increased 17.4% in the second quarter to Ps. 534.9 million, representing a 21.1% margin.
- Consolidated Net Income increased 18.1% in the second quarter to Ps. 323.2 million, compared to the same quarter of 2012. Earnings per Share[1] for the quarter increased 15.0% to Ps. 1.54, compared to the same period of 2012.
- Days of Clients improved 19 days to 135 days as of June 30, 2013, compared to 154 days as of June 30, 2012.

[1] Earnings per Share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.

Contact:
Investor Relations
Tel: +52 (55) 5081-0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Comments from the CEO

Mr. Rodrigo Herrera, Chief Executive Officer, mentioned: “We are pleased with the results achieved by the Company during this second quarter of 2013.

In this second quarter, we started seeing a recovery in our Mexican sales. We feel satisfied about having implemented the necessary strategic changes in previous quarters to improve our cash conversion cycle and cash flow generation, and we expect sales to continue recovering during the second half of the year.

On the other hand, our international operations were the main driver of growth during this second quarter, with Brazil and the United States posting the strongest results, followed by Colombia, Argentina and the rest of Latin America, all of which behaved according to our expectations. Key initiatives launched in our international operations during previous quarters, such as the recent initiative in the United States, are showing positive results. We continue to consolidate the expansion of our operations, increasing our presence in the countries where we participate.

We are convinced that the strategic decisions implemented in previous quarters were accurate and we are satisfied with the results thus far. We remain optimistic about the second half of the year, in which we expect solid growth in our international operations and a continuous recovery of our Mexican sales.”

Consolidated Results of Operations for the Second Quarter of 2013

The following table shows consolidated results of operations, in millions of pesos (except share and per-share data), and margins are shown as a percentage of Net Sales. All figures of 2013 are compared to the same period of the previous year:

For the quarter and six month period ended June 30, 2013 and 2012
(In millions of current Mexican Pesos)

	2nd Quarter			January to June		
	2013	2012	%Var	2013	2012	%Var
Net Sales	2,532.2	2,073.5	22.1	4,616.4	3,848.9	19.9
Gross Profit	1,724.6	1,357.6	27.0	3,161.4	2,592.9	21.9
Gross Margin	68.1%	65.5%	2.6	68.5%	67.4%	1.1
EBITDA[1]	534.9	455.6	17.4	864.6	742.9	16.4
EBITDA Margin	21.1%	22.0%	(0.9)	18.7%	19.3%	(0.6)
Operating Income	518.3	439.3	18.0	834.0	710.4	17.4
Operating Income Margin	20.5%	21.2%	(0.7)	18.1%	18.5%	(0.4)
Net Income of Majority Shareholders	317.0	268.7	18.0	448.3	403.3	11.1
Net Income of Majority Shareholders Margin	12.5%	13.0%	(0.5)	9.7%	10.5%	(0.8)
Weighted average number of shares outstanding	1,048,733,370	1,047,018,570	0.2	1,048,733,370	1,049,494,190	(0.1)
EPS (12 months)[2]	1.54	1.34	15.0	1.54	1.33	15.2

[1] EBITDA is calculated by adding depreciation and amortization to the Operating Income.
[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of June 30, 2013 totaled 1,048,733,370.

Net Sales rose 22.1% to Ps. 2.53 billion in the second quarter of 2013, from Ps. 2.07 billion in the second quarter of 2012.

Net Sales by brands are classified as follows:

1) **Base Brands** represent brands launched at least two years prior to the last fiscal year (2011, 2010, 2009 and earlier) in Mexico;
2) **Prior Year Launches** are brands launched during the prior fiscal year (2012) in Mexico;
3) **New Brands** are brands launched during the current fiscal year (2013) in Mexico; and
4) **International** refers to Net Sales of our international operations.

The increase in Net Sales resulted from the combination of the following factors:

i) a 1.6% decrease (Ps. 21.9 million) from **Base Brands** in Mexico during the second quarter, amounting to Ps. 1.33 billion, including line extensions;

ii) an increase of 106.7% (Ps. 69.8 million) from **Prior Year Launches** in Mexico during the second quarter due to the full year effect, including the recent line extensions of these brands, resulting in sales of Ps. 135.3 million;

iii) Ps. 35.8 million in the second quarter of 2013 from **New Brands** in Mexico; and,

iv) a 57.1% increase (Ps. 374.9 million) from **international** operations, totaling Ps. 1.03 billion in the second quarter of 2013.

Gross Profit increased 27.0% to Ps. 1.72 billion in the second quarter of 2013, compared to Ps. 1.36 billion during the second quarter of 2012. Gross Margin increased 2.6 percentage points, as a percentage of Net Sales, to 68.1% in the second quarter of 2013, compared to 65.5% in the same period of 2012. This increase in margin was primarily due to a higher participation of our over-the-counter (OTC) products, as a percentage of Net Sales, which have a lower cost of goods sold as a percentage of Net Sales.

Selling, General and Administrative Expenses, as a percentage of Net Sales, increased 3.3 percentage points to 47.7% in the second quarter of 2013, compared to 44.4% in the same period of 2012. This increase was mainly derived from higher advertising expenses in our international operations related to recent initiatives, especially in the United States, in addition to new merchandising expenses made in our Mexican operations to improve the presence of our brands at the point of sale.

EBITDA increased 17.4% to Ps. 534.9 million in the second quarter of 2013, compared to Ps. 455.6 million in the second quarter of 2012. The EBITDA margin decreased 0.9 percentage points, as a percentage of Net Sales, to 21.1% in the second quarter of 2013, from 22.0% in the same period of 2012. The EBITDA margin decreased primarily due to an higher Selling, General and Administrative Expenses (excluding Depreciation and Amortization), as a percentage of Net Sales, which was offset by a decrease in the cost of goods sold, as a percentage of Net Sales.

EBITDA Reconciliation

For the second quarter ended June 30, 2013 and 2012
(In millions of current Mexican pesos)

	Second Quarter 2013	Second Quarter 2012
Consolidated net income (loss)	323.2	273.7
Income tax expense (benefit)	139.7	148.7
Not consolidated subsidiaries (income)	(8.4)	11.9
Comprehensive financing (income) cost	63.9	5.0
Operation income	**518.3**	**439.3**
Depreciation and amortization	16.6	16.4
EBITDA	**534.9**	**455.6**
EBITDA margin	*21.1%*	*22.0%*

Operating Income increased 18.0% to Ps. 518.3 million in the second quarter of 2013, compared to Ps. 439.3 million in the second quarter of 2012. Operating Margin, as a percentage of Net Sales, decreased 0.7 percentage points, reaching 20.5% in the second quarter of 2013, from 21.2% in the same period of 2012.

Comprehensive Financing Result represented a loss of Ps. 63.9 million in the second quarter of 2013, Ps. 58.9 million more than the loss of Ps. 5.0 million recorded in the second quarter of 2012. This change was a result of: i) a Foreign Exchange gain amounting to Ps. 21.8 million during the second quarter of 2013, compared to a Ps. 39.6 million gain during the same period of 2012, resulting primarily from an appreciation of the US Dollar exchange rate vs. the Company's operating currencies, which was reflected in the Company's cash position in US Dollars; ii) an increase of Ps. 43.3 million in Financial Expenses to Ps. 72.5 million during the second quarter of 2013, compared to Ps. 29.1 million during the same period of 2012; iii) a lower Interest Income of Ps. 1.9 million during the second quarter of 2013, compared to Ps. 2.8 million in the same period of 2012; and, iv) a Ps. 15.1 million loss in the second quarter of 2013 related to the Exchange Rate conversion from our foreign operations, compared to a Ps. 18.2 million loss in the same period of 2012.

Consolidated Net Income increased 18.1% to Ps. 323.2 million in the second quarter of 2013, representing a margin of 12.8% over Net Sales, compared to Ps. 273.7 million in the second quarter of 2012, which represented a margin of 13.2%.

Balance Sheet

As of June 30, 2013, June 30, 2012 and December 31, 2012
(In millions of current Mexican pesos)

	June 30, 2013	June 30, 2012	Var Jun '13 vs Jun '12	% Var Jun '13 vs Jun'12	December 31, 2012	Var Jun '13 vs Dec '12	% Var Jun'13 vs Dec '12
Balance Sheet Information:							
Cash and Equivalents	**1,616.3**	1,398.5	217.8	15.6%	917.2	699.1	76.2%
Clients	**3,964.0**	3,726.2	237.8	6.4%	4,795.6	(831.5)	-17.3%
Inventories	**1,257.9**	1,271.8	(13.9)	-1.1%	1,032.4	225.5	21.8%
Other current Assets	**1,757.1**	735.0	1,022.1	139.1%	1,470.5	286.6	19.5%
Total Assets	**13,890.8**	10,532.5	3,358.3	31.9%	12,992.6	898.2	6.9%
Suppliers	**1,222.1**	1,213.3	8.8	0.7%	1,218.7	3.5	0.3%
Other current Liabilities	**757.3**	884.0	(126.7)	-14.3%	1,004.6	(247.4)	-24.6%
Current portion of long term debt	**1,274.0**	-	1,274.0		406.6	867.4	213.3%
Long-term Loans with financial institutions	**2,725.6**	2,420.0	305.6	12.6%	3,052.3	(326.7)	-10.7%
Total Liabilities	**6,378.0**	4,739.7	1,638.3	34.6%	5,973.8	404.2	6.8%
Stockholders Equity	**7,512.8**	5,792.9	1,720.0	29.7%	7,018.8	494.0	7.0%
Working Capital [(1)]	**6,615.9**	5,034.2	1,581.7	31.4%	5,992.4	623.5	10.4%
Working Capital less cash	**4,999.6**	3,635.7	1,363.9	37.5%	5,075.2	(75.6)	-1.5%
Accounts Receivable days	**135**	154	(19)	-12.3%	176	(41)	-23.3%
Inventories days	**139**	165	(26)	-15.8%	121	18	14.8%
Suppliers days	**135**	157	(22)	-14.3%	143	(8)	-5.7%
Cash Conversion Cycle	**139**	162	(23)	-13.9%	154	(15)	-9.7%

(1) Working Capital consists of current assets minus current liabilities.

Cash and Equivalents increased 15.6% (Ps. 217.8 million) to Ps. 1.62 billion as of June 30, 2013, compared to Ps. 1.40 billion as of June 30, 2012. This increase was mainly due to cash generated from our operations during the last twelve months, which was offset by several payments for brand acquisitions amounting to Ps. 1.48 billion, which were also financed with new loans from financial institutions.

Clients amounted to Ps. 3.96 billion as of June 30, 2013, compared to Ps. 3.73 billion as of June 30, 2012. Days of Clients decreased 19 days to 135 days as of June 30, 2013, from 154 days as of June 30, 2012. This improvement in days was the result of our hard work and dedication to our clients, mainly in Mexico, to improve our accounts receivable, which included the implementation of stricter commercial policies and negotiations with our clients. We are very satisfied to see a continuous improvement derived from these actions, as this account has been decreasing for the past two quarters.

Inventories amounted to Ps. 1.26 billion as of June 30, 2013, compared to Ps. 1.27 billion as of June 30, 2012. Days of Inventories decreased 26 days to 139 days as of June 30, 2013, compared to 165 days as of June 30, 2012. This decrease was mainly due to the more efficient inventory management the Company has achieved since the Company implemented the Warehouse Management System, in addition to the positive effect of the recently implemented strategy to outsource manufacturing of some of our products in countries outside of Mexico, which has reduced lead times and, therefore, inventory days.

Suppliers amounted to Ps. 1.22 billion as of June 30, 2013, compared to Ps. 1.21 million as of June 30, 2012. Days of Suppliers decreased 22 days to 135 as of June 30, 2013, from 157 days as of

June 30, 2012. This decrease is mainly derived from the initiation of outsourced manufacturing outside of Mexico that implied shorter payment terms to suppliers, as opposed to the same quarter of last year, in which most of the production was outsourced in Mexico. In addition, as part of the continuous effort to maximize efficiency within inventories, the Company has moved towards acquiring only finished goods from its suppliers. The implementation of this change in the outsourcing model is generating certain payments made in advance, which will decrease as this transition normalizes.

Other Current Assets amounted to Ps. 1.76 billion as of June 30, 2013, from Ps. 735.0 million as of June 30, 2012. This increase was mainly derived from advertisement paid in advance, primarily to support growth in the international operations.

Other Current Liabilities amounted to Ps. 757.3 million as of June 30, 2013, from Ps. 884.0 million as of June 30, 2012.

Loans with Financial Institutions amounted to Ps. 3.99 billion as of June 30, 2013, compared to Ps. 2.42 billion as of June 30, 2012. The current portion of long term debt amounted to Ps. 1.27 billion, which represents 31.9% of the total debt with financial institutions. As of June 30, 2013, the average debt maturity was 2.2 years and the Net Debt to EBITDA ratio was of 0.89.

Cash Conversion Cycle reached 139 days at the end of the second quarter of 2013, which represents a decrease of 23 days compared to the 162 days at the end of the same period of 2012 and a decrease of 15 days compared to December of 2012. Given the relevance of working capital in Genomma Lab's business model, management is taking all necessary actions to improve the cash conversion cycle and cash flow generation, many of which are starting to show positive effects in results.

Operations Summary

Net Sales Segmentation for the Second Quarter of 2013

During the second quarter of 2013, pharmaceutical products[1] represented 58.5% of our Mexican sales, and personal care products[2] represented 41.5%.

Net Sales of our pharmaceutical products in Mexico[1] increased 86.5% to Ps. 878.5 million during the second quarter of 2013, compared to the same period of 2012.

Net Sales of our personal care products in Mexico decreased 34.2% in the second quarter of 2013 to Ps. 622.6 million, compared to the same period of 2012.

Net Sales from our international operations increased 57.1% to Ps. 1.03 billion for the second quarter of 2013, compared to Ps. 656.2 million for the same period in 2012.

[1] Pharmaceutical products: includes OTC products and generics in Mexico. We have decided to add sales from OTC products and generics in one single segment (Pharma) since Primer Nivel, our generics line of business, is not significant enough to be viewed as a different segment and, therefore, will be considered one of our brands as part of our pharmaceutical segment.

[2] Personal care products: includes only personal care products in Mexico.

(In millions of current Mexican Pesos)

	2Q13			2Q12			
	Pharma*	PC	Total 2Q13	Pharma*	PC	Total 2Q12	%Var
Mexico	878.5	622.6	**1,501.0**	471.1	946.2	**1,417.3**	5.9%
International	370.2	661.0	**1,031.2**	100.9	555.4	**656.2**	57.1%
TOTAL	**1,248.7**	**1,283.5**	**2,532.2**	**571.9**	**1,501.6**	**2,073.5**	**22.1%**

* *Pharma* refers to OTC and generics pharmaceutical products in Mexico and OTC pharmaceutical products in the international operations.

New Product Launches and Line Extensions

During the second quarter of 2013, the Company launched 8 line extensions from our **Base Brands** and **Prior Year Launches,** and 32 new products under **New Brands.** Some of the products recently launched are:

Zan Zusi® BB Flash, a line extension of our *Zan Zusi* brand, acquired in 2012, is a make-up that hides skin stains, expression lines, open pores and imperfections. It protects against sun damage, hydrates and unifies the skin's tone, illuminates the face and helps delay premature aging.

English Lady® antiperspirants, a line extension of our *English Lady* brand, acquired in 2010, is a line of antiperspirants that are formulated for the modern woman's rhythm of life, bringing maximum protection against bad odor and perspiration; they have exclusive microcapsules that liberate prolonged fragrance and offer a sense of freshness throughout the day, maintaining the skin dry.

Fermodyl high-technology vials, a line extension of our *Fermodyl* brand, acquired in 2012, is a line of hair treatments with exclusive nanospheres that protect hair color and gradually liberate vitamins and moisturizers that penetrate to the deepest of hair throughout the day, giving a tridimensional brightness.

Other Corporate Events

- On July 8th, 2013, the Company successfully completed the issuance of debt certificates (Certificados Bursátiles "LAB 13") amounting to Ps. 2.0 billion. The certificates have a maturity of five years and will pay interest every 28 days at a coupon rate of TIIE (Tasa de Interés Interbancaria de Equilibrio) 28 days plus 0.70 percentage points. The certificates were rated "AA(mex)" by Fitch Ratings and "HR AA" by HR Ratings. The resources obtained will be used to prepay existing debt with financial institutions, improving the Company's average debt life to 4.2 years and decreasing its cost, which will be reflected as of the third quarter of 2013. This issuance is in line with the initiatives implemented to improve the Company's cash flow.

- During this quarter, Mr. Andrés Conesa Labastida, Chief Executive Officer of Grupo Aeroméxico, S.A.B. de C.V. and Independent Member of the Board of Genomma Lab since March 2012, was integrated as member of the Auditing Committee of the Company. In addition, Genomma Lab received the voluntary resignation of Mr. Fernando Paiz Andrade to his position as Member of the Board and the Auditing Committee of the Company, due to personal projects which required his attention.

- On May 20th, 2013, the Company signed a licensing agreement for the over-the-counter brand Losec A[MR]. The agreement is for 99 years. This brand has been in the market for over 25 years and is one of the leading brands in the acid inhibitors category. With this transaction, Genomma Lab consolidates its leadership in the aforementioned category. This acquisition reflects the Company's capacity to negotiate with larger players in the market, such as the multinational from which the brand was acquired.

Analyst Coverage

Actinver Casa de Bolsa S.A. de C.V.; Banco Itaú BBA, S.A.; BBVA Bancomer, S.A. Institución de Banca Múltiple; BTG Pactual US Capital LLC; Casa de Bolsa Credit Suisse S.A.; GBM Grupo Bursátil Mexicano, S.A. de C.V. Casa de Bolsa; Grupo Financiero Monex; HSBC Securities (USA) Inc.; Intercam Casa de Bolsa, S.A. de C.V.; Invex Grupo Financiero S.A. de C.V.; IXE Casa de Bolsa S.A. de C.V. Grupo Financiero Banorte; Santander Investment Securities Inc.; Signum Research; UBS Casa de Bolsa S.A. and Vector Casa de Bolsa.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Income Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the three and six month period ended on June 30, 2013 and June 30, 2012

(In thousands of current Mexican pesos)

	SECOND QUARTER		VAR	ACCUMULATED		VAR
	2013	2012	%	2013	2012	%
Net Sales	2,532,199	2,073,534	22.1%	4,616,408	3,848,885	19.9%
Costs and Expenses	807,638	715,950	12.8%	1,455,023	1,255,945	15.9%
Gross Income	**1,724,561**	**1,357,584**	**27.0%**	**3,161,385**	**2,592,940**	**21.9%**
Selling, general and administrative expenses	1,191,844	904,769	31.7%	2,305,053	1,853,579	24.4%
Other expenses	68	148	(54.1%)	464	1,132	(59.0%)
Other income	2,254	2,957	(23.8%)	8,758	4,682	87.1%
EBITDA	**534,903**	**455,624**	**17.4%**	**864,626**	**742,911**	**16.4%**
Depreciation and amortization	16,562	16,357	1.3%	30,655	32,497	(5.7%)
Income from Operations	**518,341**	**439,267**	**18.0%**	**833,971**	**710,414**	**17.4%**
Interest expense	(72,478)	(29,137)	148.7%	(146,486)	(52,619)	178.4%
Interest income	1,945	2,810	(30.8%)	3,674	7,364	(50.1%)
Exchange income (expense)	6,670	21,374	(68.8%)	(29,292)	(22,868)	28.1%
Comprehensive financing income (cost)	**(63,863)**	**(4,953)**	**1189.4%**	**(172,104)**	**(68,123)**	**152.6%**
Income (loss) of not consolidated subsidiaries	8,400	(11,894)	(170.6%)	17,118	(16,203)	(205.6%)
Income before income taxes	**462,878**	**422,420**	**9.6%**	**678,985**	**626,088**	**8.4%**
Income tax expense	139,673	148,691	(6.1%)	207,875	210,774	(1.4%)
Consolidated Net Income	**323,205**	**273,729**	**18.1%**	**471,110**	**415,314**	**13.4%**
Net income of minority stockholders	6,188	5,079	21.8%	22,839	12,012	90.1%
Net (loss) of majority stockholders	**317,017**	**268,650**	**18.0%**	**448,271**	**403,302**	**11.2%**
Conversion result from foreign currencies	57,054	42,516	34.2%	10,707	(17,547)	(161.0%)
Comprehensive Income	**374,071**	**311,166**	**20.2%**	**458,978**	**385,755**	**19.0%**

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

As of June 30, 2013, June 30, 2012, March 31, 2013 and December 31, 2012
(In thousands of current Mexican pesos)

	JUNE		VARIATION		MARCH	VARIATION		DECEMBER	VARIATION	
ASSETS	**2013**	**2012**	**JUN-12**	**%**	**2013**	**MAR-13**	**%**	**2012**	**DEC-12**	**%**
Current assets										
Cash and equivalents	1,607,911	1,368,600	239,311	17%	1,013,247	594,664	59%	884,416	723,495	82%
Restricted Fund	8,383	29,896	(21,513)	(72%)	7,651	732	10%	32,750	(24,367)	(74%)
Clients-Net	3,964,014	3,726,184	237,830	6%	4,320,242	(356,228)	(8%)	4,795,560	(831,546)	(17%)
Other accounts receivable	419,788	279,924	139,864	50%	386,746	33,042	9%	275,653	144,135	52%
Due from related parties	199,806	135,953	63,853	47%	212,395	(12,589)	(6%)	195,624	4,182	2%
Inventory - net	1,257,862	1,271,757	(13,895)	(1%)	1,078,154	179,708	17%	1,032,400	225,462	22%
Prepaid expenses	1,137,551	319,163	818,388	256%	1,143,582	(6,031)	(1%)	999,261	138,290	14%
Total current assets	**8,595,315**	**7,131,477**	**1,463,838**	**21%**	**8,162,017**	**433,298**	**5%**	**8,215,664**	**379,651**	**5%**
Non-current assets										
Trademarks	4,042,818	2,835,534	1,207,284	43%	3,726,057	316,761	9%	3,382,239	660,579	20%
Investments in subsidiaries	23,580	(10,782)	34,362	(319%)	13,925	9,655	69%	5,680	17,900	315%
Building, properties and equipment – Net	392,699	422,478	(29,779)	(7%)	395,867	(3,168)	(1%)	403,588	(10,889)	(3%)
Deferred income tax	33,433	14,270	19,163	134%	23,868	9,565	40%	14,092	19,341	137%
Other assets - net	802,945	139,553	663,392	475%	806,147	(3,202)	(0%)	971,327	(168,382)	(17%)
Total non-current assets	**5,295,475**	**3,401,053**	**1,894,422**	**56%**	**4,965,864**	**329,611**	**7%**	**4,776,926**	**518,549**	**11%**
Total assets	**13,890,790**	**10,532,530**	**3,358,260**	**32%**	**13,127,881**	**762,909**	**6%**	**12,992,590**	**898,200**	**7%**
LIABILITIES AND STOCKHOLDERS' EQUITY										
Current Liabilities										
Current portion of long term loan w/ financial institutions	1,274,036	-	1,274,036	100%	1,225,425	48,611	4%	406,621	867,415	213%
Trade accounts payable	1,222,130	1,213,283	8,847	1%	1,038,471	183,659	18%	1,218,663	3,467	0%
Due to related parties	1,291	14,619	(13,328)	(91%)	8,750	(7,459)	(85%)	9,480	(8,189)	(86%)
Other current liabilities	733,664	834,320	(100,656)	(12%)	865,195	(131,531)	(15%)	909,060	(175,396)	(19%)
Income tax payable	18,877	33,841	(14,964)	(44%)	53,077	(34,200)	(64%)	82,966	(64,089)	(77%)
Statutory employee profit sharing	3,420	1,200	2,220	185%	4,920	(1,500)	(30%)	3,110	310	10%
Total current liabilities	**3,253,418**	**2,097,263**	**1,156,155**	**55%**	**3,195,838**	**57,580**	**2%**	**2,629,900**	**623,518**	**24%**
Non-current liabilities										
Long-term loans with financial institutions	2,725,596	2,420,000	305,596	13%	2,520,088	205,508	8%	3,052,275	(326,679)	(11%)
Trade accounts payable LT	60,562	104,974	(44,412)	(42%)	60,562	-	-	60,562	-	-
Deferred income tax	336,434	116,154	220,280	190%	230,389	106,045	46%	229,370	107,064	47%
Employee retirement obligations	1,969	1,280	689	54%	1,814	155	9%	1,659	310	19%
Total liabilities	**6,377,979**	**4,739,671**	**1,638,308**	**35%**	**6,008,691**	**369,288**	**6%**	**5,973,766**	**404,213**	**7%**
Stockholders' equity										
Capital stock	1,921,660	1,921,660	-	-	1,921,660	-	-	1,921,660	-	-
Retained earnings	5,156,955	3,631,837	1,525,118	42%	5,156,955	-	-	3,592,019	1,564,936	44%
Net income	448,271	403,303	44,968	11%	131,254	317,017	242%	1,564,936	(1,116,665)	(71%)
Cumulative translation effects of foreing subsidiari	15,402	48,081	(32,679)	(68%)	(41,652)	57,054	(137%)	4,695	10,707	228%
Share buy back fund	(157,523)	(264,082)	106,559	(40%)	(158,012)	489	(0%)	(159,952)	2,429	(2%)
Net premium in placement of repurchased shares	39,749	21,748	18,001	83%	39,749	-	-	39,749	-	-
Minority interest	88,297	30,312	57,985	191%	69,236	19,061	28%	55,717	32,580	58%
Total stockholders' equity	**7,512,811**	**5,792,859**	**1,719,952**	**30%**	**7,119,190**	**393,621**	**6%**	**7,018,824**	**493,987**	**7%**
Total equity and liabilities	**13,890,790**	**10,532,530**	**3,358,260**	**32%**	**13,127,881**	**762,909**	**6%**	**12,992,590**	**898,200**	**7%**

Cash Flow

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the three and six month period ended on March 31, 2013

(In thousands of current Mexican pesos)

	JUNE 2013	
	2° QUARTER	ACCUMULATED
Cash and cash equivalents beginning of period	**1,020,898**	**917,166**
Consolidated Net Income	**323,205**	**471,110**
Charges to results with no cash flow:		
Depreciation and amortization	16,562	30,655
Income tax	139,675	207,876
Accrued interest and others	59,066	112,789
	538,508	**822,430**
Changes in Working Capital:		
Clients-Net	356,361	831,562
Inventories	(179,708)	(225,462)
Suppliers	183,593	3,447
Other current assets	(127,064)	(387,077)
Payed income tax	26,654	(127,718)
Other current liabilities	(91,924)	(47,568)
	167,912	**47,184**
Net cash generated (used) in operating activities	**706,420**	**869,614**
Investing activities:		
Investment in fixed assets	(9,493)	(18,318)
Sales of equipment	790	9,313
Brand Acquisitions	(321,459)	(602,634)
Other assets acquisitions	6,023	4,528
Net cash generated (used) in investing activities	**(324,139)**	**(607,111)**
Financing activities:		
Payments of borrowings with financial institutions	(100,000)	(100,000)
Loans with financial institutions	353,742	653,742
Interest paid	(71,804)	(105,504)
Stock Repurchase	(938)	(1,456)
Minority Interest	12,873	9,741
Net cash used in financing activities	**193,873**	**456,523**
Net increase in cash and cash equivalents before foreign exchange adjustments coming from International operations and inflationary effects.	**576,154**	**719,026**
Foreign exchange and inflationary effects from International operations	19,241	(19,898)
Accumulated cash flow at the end of the period	**1,616,294**	**1,616,294**
Less- restricted fund	8,383	8,383
Cash and cash equivalents at end of period balance for operation	**1,607,911**	**1,607,911**